LPXTI-641 is under clinical development by Lapix Therapeutics and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase I drugs for Neuromyelitis Optica (Devic’s Syndrome) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LPXTI-641’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LPXTI-641 overview
LPX-TI641 is under development for the treatment of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), rheumatoid arthritis and myelin oligodendrocyte glycoprotein antibody disease (MOGAD). The drug candidate acts as T cell immunoglobulin and mucin domain-containing protein (TIM) 3/4 receptor agonist. The drug candidate is administered through oral route.
Lapix Therapeutics overview
Lapix Therapeutics (Lapix) is a healthcare company that develops therapies to improve the immune system with modulations. Lapix is headquartered in Boston, Massachusetts, the US.
For a complete picture of LPXTI-641’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
